ProKidney Statistics
Total Valuation
ProKidney has a market cap or net worth of $543.71 million. The enterprise value is $322.55 million.
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ProKidney has 302.06 million shares outstanding. The number of shares has increased by 20.33% in one year.
| Current Share Class | 205.20M |
| Shares Outstanding | 302.06M |
| Shares Change (YoY) | +20.33% |
| Shares Change (QoQ) | +0.65% |
| Owned by Insiders (%) | 12.28% |
| Owned by Institutions (%) | 15.26% |
| Float | 156.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 611.59 |
| Forward PS | 968.61 |
| PB Ratio | 2.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 362.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.06, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.06 |
| Quick Ratio | 8.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8,871.16 |
Financial Efficiency
Return on equity (ROE) is -49.37% and return on invested capital (ROIC) is -32.91%.
| Return on Equity (ROE) | -49.37% |
| Return on Assets (ROA) | -30.15% |
| Return on Invested Capital (ROIC) | -32.91% |
| Return on Capital Employed (ROCE) | -63.16% |
| Weighted Average Cost of Capital (WACC) | 13.51% |
| Revenue Per Employee | $3,848 |
| Profits Per Employee | -$312,939 |
| Employee Count | 231 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -177,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +128.14% in the last 52 weeks. The beta is 1.70, so ProKidney's price volatility has been higher than the market average.
| Beta (5Y) | 1.70 |
| 52-Week Price Change | +128.14% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 49.30 |
| Average Volume (20 Days) | 1,062,881 |
Short Selling Information
The latest short interest is 19.24 million, so 6.37% of the outstanding shares have been sold short.
| Short Interest | 19.24M |
| Short Previous Month | 18.26M |
| Short % of Shares Out | 6.37% |
| Short % of Float | 12.26% |
| Short Ratio (days to cover) | 23.69 |
Income Statement
In the last 12 months, ProKidney had revenue of $889,000 and -$72.29 million in losses. Loss per share was -$0.53.
| Revenue | 889,000 |
| Gross Profit | 889,000 |
| Operating Income | -168.55M |
| Pretax Income | -156.46M |
| Net Income | -72.29M |
| EBITDA | -161.92M |
| EBIT | -168.55M |
| Loss Per Share | -$0.53 |
Full Income StatementBalance Sheet
The company has $224.94 million in cash and $3.78 million in debt, with a net cash position of $221.16 million or $0.73 per share.
| Cash & Cash Equivalents | 224.94M |
| Total Debt | 3.78M |
| Net Cash | 221.16M |
| Net Cash Per Share | $0.73 |
| Equity (Book Value) | 263.10M |
| Book Value Per Share | -7.21 |
| Working Capital | 208.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$132.21 million and capital expenditures -$17.85 million, giving a free cash flow of -$150.06 million.
| Operating Cash Flow | -132.21M |
| Capital Expenditures | -17.85M |
| Depreciation & Amortization | 6.63M |
| Net Borrowing | -17,000 |
| Free Cash Flow | -150.06M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -18,959.73% |
| Pretax Margin | -17,599.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProKidney does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.33% |
| Shareholder Yield | -20.33% |
| Earnings Yield | -13.30% |
| FCF Yield | -27.60% |
Analyst Forecast
The average price target for ProKidney is $6.25, which is 247.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.25 |
| Price Target Difference | 247.22% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 327.50% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ProKidney has an Altman Z-Score of -1.51 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.51 |
| Piotroski F-Score | 1 |
